Fredun Pharmaceuticals Limited (BOM:539730)

Market Cap	13.22B +303.4%
Revenue (ttm)	6.39B +40.8%
Net Income	326.21M +65.3%
EPS	61.23 +44.0%
Shares Out	5.51M
PE Ratio	39.16
Forward PE	n/a
Dividend	0.70 (0.03%)
Ex-Dividend Date	Sep 23, 2025

Volume	34,744
Open	2,399.00
Previous Close	2,397.80
Day's Range	2,173.30 - 2,423.00
52-Week Range	690.00 - 2,620.00
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	May 25, 2026

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 261
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 539730

Financial Performance

In fiscal year 2026, Fredun Pharmaceuticals's revenue was 6.39 billion, an increase of 40.83% compared to the previous year's 4.54 billion. Earnings were 326.21 million, an increase of 65.26%.